A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life

PHASE4CompletedINTERVENTIONAL
Enrollment

277

Participants

Timeline

Start Date

March 28, 2019

Primary Completion Date

February 1, 2021

Study Completion Date

November 3, 2021

Conditions
Psoriasis
Interventions
DRUG

Apremilast

Apremilast 30 mg tablets taken orally twice a day.

DRUG

Placebo

Placebo tablets taken orally twice a day

Trial Locations (72)

1011

Research Site, Lausanne

8091

Research Site, Zurich

10117

Research Site, Berlin

10247

Research Site, Berlin

12004

Research Site, Castellon

13086

Research Site, Berlin

13507

Research Site, Berlin

15706

Research Site, Santiago de Compostela

16132

Research Site, Genova

20122

Research Site, Milan

20246

Research Site, Hamburg

23538

Research Site, Lübeck

24105

Research Site, Kiel

26953

Research Site, Valence

27003

Research Site, Lugo

28040

Research Site, Madrid

28922

Research Site, Alcorcón

28942

Research Site, Fuenlabrada

30008

Research Site, Murcia

31059

Research Site, Toulouse

33075

Research Site, Bordeaux

35043

Research Site, Marburg

37007

Research Site, Salamanca

38043

Research Site, Grenoble

40138

Research Site, Bologna

41013

Research Site, Seville

41014

Research Site, Seville

42270

Research Site, Saint-Priest-en-Jarez

44803

Research Site, Bochum

46940

Research Site, Manises

52074

Research Site, Aachen

53111

Research Site, Bonn

60590

Research Site, Frankfurt am Main

69115

Research Site, Heidelberg

69437

Research Site, Lyon

72037

Research Site, Valenciennes

72076

Research Site, Tübingen

74374

Research Site, Pringy

75475

Research Site, Paris

76031

Research Site, Rouen

80131

Research Site, Napoli, Campania

80138

Research Site, Napoli

80802

Research Site, München

86179

Research Site, Augsburg

89081

Research Site, Ulm

89129

Research Site, Langenau

91054

Research Site, Erlangen

95123

Research Site, Catania

07548

Research Site, Gera

07743

Research Site, Jena

06129

Research Site, Perugia

00133

Research Site, Roma

00168

Research Site, Roma

08916

Research Site, Badalona

03010

Research Site, Alicante

EN5 3DJ

Research Site, Barnet

B15 2WB

Research Site, Birmingham

BN2 3EW

Research Site, Brighton

IP33 2QZ

Research Site, Bury St Edmunds

DG1 4AP

Research Site, Dumfries

DD1 9SY

Research Site, Dundee

EX2 5DW

Research Site, Exeter

GL1 3NN

Research Site, Gloucester

TW7 6AF

Research Site, Isleworth

LS7 4SA

Research Site, Leeds

SE1 9RT

Research Site, London

NP18 3XQ

Research Site, Newport

NG7 2UH

Research Site, Nottingham

PL6 8DH

Research Site, Plymouth

RH1 5RH

Research Site, Redhill

SO16 6YD

Research Site, Southampton

DY8 4JB

Research Site, Stourbridge

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03774875 - A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life | Biotech Hunter | Biotech Hunter